百时美施贵宝：拟41亿美元收购RayzeBio 加强抗癌药物业务

观点地产网2023-12-27

观点网讯：12月27日，百时美施贵宝（Bristol Myers Squibb）日前表示，将以约41亿美元收购RayzeBio，即以每股62.50美元的现金大幅溢价收购，以加强其抗癌药物业务。通过这笔交易，百时美施贵宝将获得RayzeBio的晚期靶向癌症疗法RYZ101，该疗法通过将杀死细胞的放射性粒子与附着在肿瘤上的分子结合起来发挥作用。据悉，此前百时美施贵宝同意以140亿美元收购...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2394519788?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2023-12-27 16:01","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2394519788","market":"us","top_or_hot":-1,"title":"百时美施贵宝：拟41亿美元收购RayzeBio 加强抗癌药物业务","media":"观点地产网","content":"<div>\n<p>观点网讯：12月27日， 百时美施贵宝 （Bristol Myers Squibb）日前表示，将以约41亿美元收购RayzeBio，即以每股62.50美元的现金大幅溢价收购，以加强其 抗癌药物 业务。通过这笔交易，百时美施贵宝将获得RayzeBio的晚期靶向癌症疗法RYZ101，该疗法通过将杀死细胞的放射性粒子与附着在肿瘤上的分子结合起来发挥作用。据悉，此前百时美施贵宝同意以140亿美元收购...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20231227161740817fdcc7&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>百时美施贵宝：拟41亿美元收购RayzeBio 加强抗癌药物业务</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n百时美施贵宝：拟41亿美元收购RayzeBio 加强抗癌药物业务\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-12-27 16:01 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20231227161740817fdcc7&s=b><strong>观点地产网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>观点网讯：12月27日， 百时美施贵宝 （Bristol Myers Squibb）日前表示，将以约41亿美元收购RayzeBio，即以每股62.50美元的现金大幅溢价收购，以加强其 抗癌药物 业务。通过这笔交易，百时美施贵宝将获得RayzeBio的晚期靶向癌症疗法RYZ101，该疗法通过将杀死细胞的放射性粒子与附着在肿瘤上的分子结合起来发挥作用。据悉，此前百时美施贵宝同意以140亿美元收购...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20231227161740817fdcc7&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1670711040.USD","symbol_name":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20231227161740817fdcc7&s=b","article_id":"2394519788","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20231227161740817fdcc7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2394519788","pubTimestamp":1703664069,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"观点网讯：12月27日， 百时美施贵宝 日前表示，将以约41亿美元收购RayzeBio，即以每股62.50美元的现金大幅溢价收购，以加强其 抗癌药物 业务。通过这笔交易，百时美施贵宝将获得RayzeBio的晚期靶向癌症疗法RYZ101，该疗法通过将杀死细胞的放射性粒子与附着在肿瘤上的分子结合起来发挥作用。据悉，此前百时美施贵宝同意以140亿美元收购精神分裂症药物开发商Karuna Therapeutics。百时美施贵宝于1982年进入中国市场，成立了改革开放后第一家中美合资制药企业。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1670711040.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) ACC","LU1032466523.USD":"高盛全球多资产收益组合Acc","BK4532":"文艺复兴科技持仓","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4585":"ETF&股票定投概念","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","BK4534":"瑞士信贷持仓","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","BK4139":"生物科技","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","BK4007":"制药","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","RYZB":"RayzeBio, Inc.","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","BK4559":"巴菲特持仓","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","BK4588":"碎股","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","LU0237698245.USD":"富达环球地产基金A","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1670710588.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) ACC","BK4581":"高盛持仓","LU1670710661.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) INC","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU1670711123.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) INC","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","LU0882574055.USD":"富达全球健康医疗A ACC","BMY":"施贵宝","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H"},"translate_title":"Bristol-Myers Squibb: Plans to acquire RayzeBio for $4.1 billion to strengthen anticancer drug business","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RYZB":1,"BMY":1},"content_text":"观点网讯：12月27日， 百时美施贵宝 （Bristol Myers Squibb）日前表示，将以约41亿美元收购RayzeBio，即以每股62.50美元的现金大幅溢价收购，以加强其 抗癌药物 业务。通过这笔交易，百时美施贵宝将获得RayzeBio的晚期靶向癌症疗法RYZ101，该疗法通过将杀死细胞的放射性粒子与附着在肿瘤上的分子结合起来发挥作用。据悉，此前百时美施贵宝同意以140亿美元收购精神分裂症药物开发商Karuna Therapeutics（KRTX.US）。资料显示。百时美施贵宝是一家以“研发并提供创新药物，帮助患者战胜严重疾病”为使命的全球性生物制药公司。公司致力于为患者提供革新性药物，以治疗严峻且具有挑战性的疾病。百时美施贵宝于1982年进入中国市场，成立了改革开放后第一家中美合资制药企业。在过去40年间，已为中国患者带来了超过40款创新的治疗选择，涉及肿瘤学、血液学、病毒学以及心血管等疾病领域。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2394519788"}